AlphaYou
Overview
Key stats
Fundamentals Sep 10- Open
- $125.66
- 52-wk high
- $132.60
- High
- $127.72
- 52-wk low
- $81.09
- Low
- $123.57
- Prev close
- $124.40
- Mkt cap
- $25.54B
- P/E
- 15.8x
- Volume
- 1.30M
- Fwd P/E
- 14.4x
- Beta
- 0.77
- P/S
- 4.4x
- P/B
- 4.0x
- Profit margin
- +27.7%
- Op margin
- +41.9%
- ROE
- +30.7%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Earnings
Earnings came in 59.1% above what analysts expected.
Earnings per share
$1.76 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
FY2026 guidance
$5.13B to $5.26B
No comparable estimate
Reports Oct 27, 2026, in 47 days
EPS expected
-$4.16 to -$2.34
Revenue expected
19 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.37B | $1.51B | $1.27B | $1.67B |
| Cost of what it sold | $99.0M | $121.1M | $104.5M | $105.0M |
| Gross profit | $1.27B | $1.39B | $1.17B | $1.57B |
| What it spent | ||||
| Research and development | $506.6M | $611.4M | $515.9M | $517.0M |
| Sales and admin | $329.1M | $390.4M | $328.1M | $351.7M |
| Total operating expenses | $835.7M | $1.00B | $844.0M | $871.2M |
| What was left | ||||
| Operating profit | $431.3M | $384.0M | $324.2M | $697.9M |
| Interest on debt | $592.0K | $582.0K | $569.0K | $581.0K |
| Profit before tax | $482.3M | $389.9M | $343.6M | $751.5M |
| Tax | $58.1M | $90.7M | $40.3M | $165.9M |
| Net profit | $424.2M | $299.3M | $303.3M | $585.6M |
| EBITDA | $506.9M | $414.5M | $368.0M | $752.1M |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
85 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is bullish
Tone of tracked coverage
Incyte to Present at Upcoming Investor Conferences
NeutralSep 2Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains
NeutralSep 1Incyte (NASDAQ: INCY) expects to sidestep new CMS drug pricing rules
BullishSep 1Incyte agrees CMS pricing deal for Jakafi, avoids certain future mandates; no change to 2026 guidance
Leans bullishSep 1Incyte (INCY) Enters Agreement With CMS to Improve Medicaid Acce
Leans bullishSep 1H.C. Wainwright reiterates Incyte stock rating on Medicaid pricing deal
Leans bullishSep 1FDA OKs Takeda, Protagonist drug for rare blood cancer
NeutralAug 31Incyte Stock Price Forecast. Should You Buy INCY?
BullishAug 29
Macro
20 macro signals shaping INCY right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results